ROKIT Healthcare, a corporation based on artificial intelligence (AI) long-term regeneration platform, is strong in early trading on the 3rd. It is interpreted that buying interest surged following news of the successful clinical trial for AI skin cancer regeneration therapy.
As of 9:32 a.m., ROKIT Healthcare is trading at 17,080 won, up 2,040 won (13.56%) from the previous trading day.
ROKIT Healthcare announced today that it officially unveiled the world's first successful case of skin cancer regeneration treatment technology clinical trial in Japan. At the 17th Japanese Society of Wound Surgery held in Tokyo, ROKIT Healthcare revealed a case where an elderly skin cancer patient, for whom traditional surgery and transplantation were impossible, completely rebuilt normal skin tissue in four weeks using only AI regeneration therapy.
The clinical trial was conducted and presented directly by Hajime Matsumura, president of the Japanese Society of Wound Surgery and a professor at Tokyo Medical University. The results were officially published in the SCI international journal "Journal of Clinical Medicine."
The company explained that there was no immune rejection response from the patients and that scars were minimal. Notably, this technology's ability to be applicable to elderly patients or those for whom existing treatments were impossible due to systemic diseases is a significant advantage.
A ROKIT Healthcare official said, "Based on this achievement, we plan to launch the commercial use of the AI skin regeneration platform in key global regions including Japan, Korea, the United States, Europe, and South America starting in the second half of this year."